| Asthma
Breo Ellipta vs Nucala
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Breo Ellipta vs Nucala with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNucala has a higher rate of injection site reactions vs Breo Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nucala but not Breo Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breo Ellipta
Nucala
At A Glance
Oral inhalation
Once daily
ICS/LABA combination
SC injection
Every 4 weeks
IL-5 antagonist
Indications
- Chronic Obstructive Airway Disease
- Asthma
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Chronic Obstructive Airway Disease
- Eosinophilic granulomatosis with polyangiitis
- Hypereosinophilic syndrome
Dosing
Chronic Obstructive Airway Disease 1 actuation of BREO ELLIPTA 100/25 mcg once daily by oral inhalation; use a short-acting beta2-agonist for breakthrough symptoms between doses.
Asthma Adults >=18 years: 1 actuation of BREO ELLIPTA 100/25 mcg or 200/25 mcg once daily by oral inhalation; pediatric patients 12-17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily; pediatric patients 5-11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily; maximum dose is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily.
Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.
Asthma (6-11 years) 40 mg SC once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any excipient
- History of hypersensitivity to mepolizumab or excipients in the formulation
Adverse Reactions
Most common (>=3%) nasopharyngitis, upper respiratory tract infection, oropharyngeal candidiasis, headache, back pain, pneumonia, bronchitis, sinusitis, cough, arthralgia, influenza, pharyngitis, pyrexia
Serious serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia, immunosuppression, hypercorticism, adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, growth effects, glaucoma, cataracts
Postmarketing palpitations, tachycardia, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, nervousness, paradoxical bronchospasm
Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema
Serious herpes zoster
Postmarketing hypersensitivity reactions including anaphylaxis
Pharmacology
Breo Ellipta combines fluticasone furoate, a synthetic trifluorinated ICS that inhibits inflammation via glucocorticoid receptor activation, with vilanterol, a LABA that relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors and increasing intracellular cyclic AMP.
Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breo Ellipta
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (10/12)
Nucala
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Breo Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Nucala
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Breo Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Nucala
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breo Ellipta.
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Breo ElliptaView full Breo Ellipta profile
NucalaView full Nucala profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.